The current financial score of OptimizeRx Corp is 6.89. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 20.50M, representing a year-over-year decrease of 29.77%, while its net profit experienced a year-over-year decrease of 145.89%.
The current valuation score of OptimizeRx Corp is 6.89. Its current P/E ratio is 20.58, which is 18468.18% below the recent high of 3821.76 and 296.33% above the recent low of -40.41.
The current earnings forecast score of OptimizeRx Corp is 8.67. The average price target is 12.40, with a high of 18.00 and a low of 10.00.
The current price momentum score of OptimizeRx Corp is 4.07. Currently, the stock price is trading between the resistance level at 8.35 and the support level at 6.86, making it suitable for range-bound swing trading.
The current institutional shareholding score of OptimizeRx Corp is 7.00. The latest institutional shareholding proportion is 82.46%, representing a quarter-over-quarter increase of 8.32%. The largest institutional shareholder is Chuck Royce, holding a total of 1.09M shares, representing 0.05% of shares outstanding, with 46.24% decrease in holdings.
The current risk assessment score of OptimizeRx Corp is 3.58. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.